Cover Image
市場調查報告書

葡萄膜惡性黑色素瘤(Melanoma):開發中產品分析

Uveal Melanoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 302507
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
Back to Top
葡萄膜惡性黑色素瘤(Melanoma):開發中產品分析 Uveal Melanoma - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 129 Pages
簡介

葡萄膜惡性黑色素瘤(Melanoma)是最常見的眼球內朣瘤,是癌(朣瘤)細胞出現在被稱作葡萄膜的眼球部分的疾病。葡萄膜包含有形成黑色素的黑色素細胞(melanocytes)。這個黑色素細胞一旦癌化,就被稱為黑色素瘤。其症狀有虹膜上的暗斑、青光眼、眼痛、眼睛發紅等。

本報告提供葡萄膜惡性黑色素瘤(Melanoma)治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

葡萄膜惡性黑色素瘤(Melanoma)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

葡萄膜惡性黑色素瘤(Melanoma):企業開發中的治療藥

葡萄膜惡性黑色素瘤(Melanoma):大學/機關研究中的治療藥

葡萄膜惡性黑色素瘤(Melanoma):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

葡萄膜惡性黑色素瘤(Melanoma):企業開發中的產品

葡萄膜惡性黑色素瘤(Melanoma):大學/機關研究中的產品

葡萄膜惡性黑色素瘤(Melanoma)的治療藥開發企業

  • Aura Biosciences, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Eli Lilly and Company
  • Immunocore Limited
  • Navigen Pharmaceuticals, Inc.
  • Novartis AG
  • PEP-Therapy SAS
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

葡萄膜惡性黑色素瘤(Melanoma):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

葡萄膜惡性黑色素瘤(Melanoma):最近的開發平台趨勢

葡萄膜惡性黑色素瘤(Melanoma):暫停中的計劃

葡萄膜惡性黑色素瘤(Melanoma):中止開發的產品

葡萄膜惡性黑色素瘤(Melanoma):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9207IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H1 2017, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveal Melanoma - Overview
    • Uveal Melanoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Uveal Melanoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Uveal Melanoma - Companies Involved in Therapeutics Development
    • Bellicum Pharmaceuticals Inc
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics Inc
    • Cleveland BioLabs Inc
    • Delcath Systems Inc
    • Eli Lilly and Company
    • Iconic Therapeutics Inc
    • Immunocore Ltd
    • Lion Biotechnologies Inc
    • Navigen Inc
    • Novartis AG
    • PEP-Therapy SAS
    • Pfizer Inc
    • Polaris Pharmaceuticals Inc
    • Spectrum Pharmaceuticals Inc
    • Syndax Pharmaceuticals Inc
  • Uveal Melanoma - Drug Profiles
    • AU-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hI-con1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMCgp-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab + nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXS-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melphalan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nutlin-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegargiminase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEP-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Uveal Melanoma - Dormant Projects
  • Uveal Melanoma - Discontinued Products
  • Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress
      • Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
      • Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
      • Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
      • Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
      • Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme
      • Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma
      • May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
      • May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma
      • Apr 14, 2015: Navigen Announces Phase I SBIR Award to Support Development of Uveal Melanoma Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Uveal Melanoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Uveal Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H1 2017
  • Uveal Melanoma - Pipeline by Delcath Systems Inc, H1 2017
  • Uveal Melanoma - Pipeline by Eli Lilly and Company, H1 2017
  • Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H1 2017
  • Uveal Melanoma - Pipeline by Immunocore Ltd, H1 2017
  • Uveal Melanoma - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Uveal Melanoma - Pipeline by Navigen Inc, H1 2017
  • Uveal Melanoma - Pipeline by Novartis AG, H1 2017
  • Uveal Melanoma - Pipeline by PEP-Therapy SAS, H1 2017
  • Uveal Melanoma - Pipeline by Pfizer Inc, H1 2017
  • Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Uveal Melanoma - Dormant Projects, H1 2017
  • Uveal Melanoma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Uveal Melanoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top